Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announces actions to strengthen its
competitive position. These actions are expected to deliver structural cost
savings of up to EUR 100 million per year by 2010. In addition, DSM is also
taking a number of measures to address the current more difficult market
conditions. These market conditions together with the decision to currently
prioritize cash over short term profitability are resulting in a revised full
year guidance for 2008 operating profit of above EUR 900 million, around 10%
higher compared to 2007 and a record result for the company.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announces that a definitive agreement
has been signed to sell its Solutech business to Lydall, Inc., the United
States-based specialty engineered products manufacturer. Financial details of
the transaction will not be disclosed.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announces that DSM Nutritional
Products has opened its third premix plant in China. The new facility allows
DSM to serve a larger geographical area in China. This enables the company to
capitalize on opportunities that arise from the rapidly growing animal
nutrition & health industry in one of the key growth countries for DSM.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, announces today that it has reached an
agreement with the management of DSM Deretil on a management buy-out. DSM
Deretil is a business unit of DSM Anti-Infectives. Financial details will not
be disclosed.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, announces today that Ad Overbeek, Global
Science Manager DSM NeoResins+, has been selected by The Federation of
Societies for Coatings Technology (FSCT) to deliver the 2009 Joseph J.
Mattiello Memorial Lecture.
Continued strong organic sales growth (12%), driven by pricing power.
Sustained strong profitability in Nutrition. Accelerating economic downturn
increasingly visible in Materials Sciences. EBIT from continuing operations up
27% to EUR 267 million; EPS up 41%. 2008 operating profit expected to be
around EUR 1,000 million.
DSM and the Dutch Olympic Committee/Dutch Sports Federation (NOC*NSF) will
continue to be ‘Partners in Sports’ in the run-up to the London 2012 Olympics.
The partners have today signed an agreement to this effect at the Papendal
Dutch National Sports Centre. As innovation partner of NOC*NSF, DSM is
supporting the Dutch Olympic team with innovations in the field of nutrition
and materials in order to help the team achieve top performances.
Royal DSM N.V., the global Life Sciences and Materials Sciences company today
announced the execution of a multimillion dollar cooperative funding agreement
with the US Department of Energy to underwrite a portion of research and
development costs aimed at enabling “second generation” biofuels from non-food
feedstocks.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, and the United Nations World Food Programme
(WFP) announce that the 2008 ICIS Innovation Awards for Best Business
Innovation has been awarded to DSM Nutritional Products and WFP for the MixMe™
micronutrient powder.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announces
that it has made an investment in the new business incubator in the field of
medical devices Accelerated Technologies II, L.P. (ATP). The investment
further strengthens DSM’s position in the biomedical materials market, one of
the Emerging Business Areas defined in its Vision 2010 – Building on Strengths
strategy. Financial details will not be disclosed.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announces that DSM Anti-Infectives has
decided to close its site in Strängnäs, Sweden. The site mainly produces
clavulanic acid. Total cost of closure will be slightly above EUR 10 million
(after tax) and will be reported as an exceptional item in Q4.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announces that the renowned scientific
journal “Nature Biotechnology” is publishing a paper in its October 2008 issue
on a breakthrough analysis of the DNA sequence of the fungus Penicillium
chrysogenum. The paper is the result of a major research project initiated by
DSM in which seven international research groups participated.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announces
that it has made an equity investment in The Compliers Group International
B.V. (TCG). The Netherlands-based company focuses on the development of smart
pharmaceutical packaging solutions that contain microchips which enable the
monitoring of a patient’s therapy compliance. Financial details of the
investment will not be disclosed.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, will update analysts and investors at its
annual conference in Vaalsbroek on 25 and 26 September 2008 on the progress
made in its Vision 2010 strategy. DSM is also updating its 2008 EBIT guidance
today, from EUR 970 million, with potential upside, to EUR 1,025-1,075 million
on the back of continued strength in some of DSM’s businesses, particularly
DSM Agro.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in The Netherlands, today announces that the second
polymerization plant for Stanyl® polyamide 46 on the Chemelot site in Geleen
(Netherlands) has opened. The new plant doubles DSM’s worldwide production
capacity for this high-performance plastic, supporting expected continuous
strong growth in the coming years based on the leading position of Stanyl® in
electronics and the growing usage in automotive applications due to higher
demand for metal replacement. DSM has invested several tens of millions of
euros in the new plant.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in The Netherlands, today announces a major capacity expansion
for its innovative picture glass ®claryl. Within a year after its launch,
market demand for this innovative product has risen so quickly that DSM
decided to build an additional oven at its manufacturing facility in Geleen,
the Netherlands, increasing production capacity by 50%.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announces that DSM Biomedical and
Caliber Therapeutics, Inc. will partner on the development of a novel drug
delivery balloon catheter that can be used to treat vascular diseases such as
atherosclerosis. This cooperation is another step for DSM to leverage its
competences in Materials Sciences into Life Sciences applications.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in The Netherlands, has successfully increased its outstanding
EUR 300 million 4.00% bond due 2015 by EUR 200 million. The increase,
triggered by interest of investors, has been placed to institutional investors
across Europe.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announces the inauguration of its new
polymer plant in Jiangyin (Jiangsu province, China).
Royal DSM N.V., the global Life Sciences and Materials Sciences Company
headquartered in the Netherlands, today announces the closure of its citric
acid manufacturing plant in Wuxi (China) by Q1 2009.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announces
that it has acquired an equity stake of 29.3% in Provexis plc, an AIM listed
company that develops and licenses ingredients for the functional food,
medical food and dietary supplement market. The investment makes DSM the
largest shareholder of Provexis.
Royal DSM N.V. has appointed Mrs A.M. (Margo) Vliegenthart as member of the
Supervisory Board of DSM Nederland B.V. (“DSM Netherlands”) with effect from 1
August 2008. Mrs Vliegenthart fills the vacancy caused by the untimely death
of Mr M.A.M. (Thijs) Wöltgens earlier this year.
Very strong Q2 result based on 17% organic sales growth. Changing dynamics in
vitamin business drive significantly higher profitability in Life Sciences.
Materials Sciences performing well against difficult economic background. EBIT
from continuing operations up 19% to EUR 276 million. Earnings per share 34%
higher. Guidance raised: 2008 EBIT from continuing operations expected to be
around EUR 970 million, with potential upside. Execution of Vision 2010
strategy fully on track.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announces the acquisition of the
business and substantially all of the assets of Valley Research Inc. of South
Bend Indiana, United States. Through this acquisition, DSM further reinforces
its leading global position in food enzymes.
Royal DSM N.V. has repurchased 534,797 of its own shares in the period from 3
July 2008 up to and including 8 July 2008 at an average price of EUR 35.90.
This is in accordance with the second phase of the share buyback program,
announced on 5 May 2008.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today reports that an interruption in
production that occurred at DSM Agro last month will take longer to end than
originally anticipated. In view of the current positive business climate the
outlook will not be lowered due to this event.
Royal DSM N.V. has repurchased 860,787 of its own shares in the period from 26
June 2008 up to and including 2 July 2008 at an average price of EUR 37.22.
This is in accordance with the second phase of the share buyback program,
announced on 5 May 2008.
Craig J. Hawker, Professor of Chemistry, Biochemistry and Materials and
Director of the Materials Research Laboratory at the University of California,
Santa Barbara, USA, has been awarded the DSM Performance Materials Award 2008
in recognition of his exceptional contributions to the advancement of the
materials sciences.
Royal DSM N.V. has repurchased 749,000 of its own shares in the period from 19
June 2008 up to and including 25 June 2008 at an average price of EUR 38.21.
This is in accordance with the second phase of the share buyback program,
announced on 5 May 2008.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announces that its Scotland based
vitamin manufacturing facility has been awarded the Carbon Trust Standard
certification.
Royal DSM N.V. has repurchased 896,247 of its own shares in the period from 12
June 2008 up to and including 18 June 2008 at an average price of EUR 39.91.
This is in accordance with the second phase of the share buyback program,
announced on 5 May 2008.
DSM Biologics and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX)
today announce another breakthrough in the production of IgG antibodies using
PER.C6® technology. By employing the PER.C6® human cell line and proprietary
XD™ technology, a record yield of over 27 grams per liter has been achieved.
In March 2008 a yield of 15 grams per liter was reported.
Royal DSM N.V. has repurchased 783,673 of its own shares in the period from 5
June 2008 up to and including 11 June 2008 at an average price of EUR 38.96.
This is in accordance with the second phase of the share buyback program,
announced on 5 May 2008.
Royal DSM N.V. has repurchased 769,914 of its own shares in the period from 29
May 2008 up to and including 4 June 2008 at an average price of EUR 39.17.
This is in accordance with the second phase of the share buyback program,
announced on 5 May 2008.
Royal DSM N.V. has repurchased 560,166 of its own shares in the period from 22
May 2008 up to and including 28 May 2008 at an average price of EUR 37.40.
This is in accordance with the second phase of the share buyback program,
announced on 5 May 2008.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announces that it has closed the
acquisition of The Polymer Technology Group, Inc. (PTG) of Berkeley
(California, United States), a market leader in the field of biomedical
polymers.
Royal DSM N.V. has repurchased 671,891 of its own shares in the period from 15
May 2008 up to and including 21 May 2008 at an average price of EUR 36.81.
This is in accordance with the second phase of the share buyback program,
announced on 5 May 2008.
Royal DSM N.V. has repurchased 490,192 of its own shares in the period from 8
May 2008 up to and including 14 May 2008 at an average price of EUR 35.59.
This is in accordance with the second phase of the share buyback program,
announced on 5 May 2008.
Royal DSM N.V. has repurchased 298,333 of its own shares in the period from 5
May 2008 up to and including 7 May 2008 at an average price of EUR 35.46. This
is in accordance with the second phase of the share buyback program, announced
on 5 May 2008.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, announces that the company will today, 5 May
2008, start the second phase of the share buy-back program of EUR 750 million
announced on 27 September 2007.
Organic sales growth 14% due to strong business positions and favorable market
conditions. EBIT from continuing operations up 22% despite lower US dollar and
higher feedstock prices. Earnings per share up 42%. Execution of Vision 2010
strategy fully on track. Resumption of share buy-back program for next EUR 250
million as of 5 May. Outlook: 2008 EBIT expected to be EUR 870 million +/- 5%.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announces an agreement to acquire The
Polymer Technology Group, Inc. (PTG) of Berkeley (California, United States).
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announced the opening of the market
development plant for PA4T, the new polymer for use in electronics and other
applications. The plant is operational as of today.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, today announces plans for a substantial
capital expenditure program, expected to involve up to USD 450 million.
Royal DSM N.V. announces the following management appointments: Jos Goessens
(1951), at present Business Group Director DSM Engineering Plastics, has been
appointed Director Strategic Projects, reporting to the Managing Board. Roelof
Westerbeek (1963) has been appointed Business Group Director DSM Engineering
Plastics with effect from 1 October 2008.
Royal DSM N.V. today provides the investment community with comparative
figures for 2007 that reflect the company’s new cluster structure as of 1
January 2008. The new structure was announced in September 2007 and is a
result of the acceleration of DSM’s strategy Vision 2010 – Building on
Strengths.
The DSM Annual General Meeting of Shareholders on 26 March 2008 passed a
resolution to declare a dividend for 2007 of EUR 1.20 per ordinary share of
EUR 1.50 par value. An interim dividend of EUR 0.33 per ordinary share having
been paid on 22 August 2007, the final dividend for 2007 will amount to EUR
0.87 per ordinary share.
Royal DSM N.V. is today presenting its fifth annual sustainability report: the
Triple P (People, Planet, Profit) Report 2007 entitled Embracing the Future.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has made an equity investment in the Dutch company IQ Therapeutics B.V.
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced
that it has participated in a USD 20 million financing round in Tianjin Green
Bio-Science Co., Ltd (China).
The Dutch Ministers Cramer (Housing, Spatial Planning and the Environment) and
Eurlings (Transport, Public Works and Water Management) and DSM today announce
that they have reached an agreement in principle on the termination of ammonia
transport by rail between Geleen and IJmuiden.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, has reached an agreement in principle with
Arsenal Capital Partners (United States) on the sale of DSM Special Products
BV.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, has received a grant from the US Department
of Energy for a technical consortium on an innovative biotechnological
approach of bioproducts and biofuels.
Strong Q4 results based on 10% organic sales growth. Operating profit for 2007
of EUR 823 million in line with expectations. Net profit before exceptional
items at EUR 558 million, better than last year; EPS 8% higher. Proposed
dividend EUR 1.20 per ordinary share (+20%). Outlook: Operating profit before
exceptional items in 2008 expected to approach level achieved in 2007.
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, and the French starch and starch-derivatives
company ROQUETTE have joined forces to implement and commercialize the
fermentative production of biorenewable succinic acid, which – amongst other
applications - opens the possibility to produce bio-based performance
materials.
Royal DSM N.V., the leading Life Sciences and Materials Sciences company from
the Netherlands, today announces the acquisition of the US-based company
Soluol, a developer, producer and marketer of high performance urethane resins
which are used in a wide range of applications, with annual sales of USD 20
million.
Royal DSM N.V., the leading Life Sciences and Materials Sciences company from
the Netherlands, today announces that it will invest nearly EUR 15 million in
the construction of a new plant for the production of wet polyesters and other
specialty resins in Meppen, Germany.